Asymmetric dimethylarginine levels in patients with coronary artery ectasia

Kardiologia Polska

Volumn 67, Issue 12, 2009, Pages 1362-1368

  Cay, Serkan ^a   Cagirci, Goksel ^b   Akcay, Murat ^c   Karakurt, Ozlem ^b   Kahraman, Erkan ^a   Yazihan, Nuray ^d   Canga, Aytun ^a   Akdemir, Ramazan ^b   Aydogdu, Sinan ^a  

^a Yuksek Ihtisas Heart Education and Research Hospital   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

^c ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d ANKARA UNIVERSITY   (Turkey)

Author keywords

Asymmetric dimethylarginine; Coronary artery ectasia; Endothelial dysfunction

Indexed keywords

N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; CORONARY ARTERY ECTASIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE;

EID: 74549200357     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Markis JE, Joffe CD, Cohn PF, et al. Clinical significance of coronary artery ectasia. Am J Cardiol 1976; 37: 217-22.
2. Hartnell GG, Parnell PM, Pridie RB. Coronary artery ectasia, its prevalence and clinical significance in 4993 patients. Br Heart J 1985; 54: 392-5.
3. Principal Investigators of CASS and their Associates. National Heart, Lung, and Blood Institute Coronary Artery Surgery Study. Circulation 1981; 63 (Suppl. II): I1-1.
4. Kruger D, Stierle U, Herrmann G, et al. Exercise-induced myocardial ischemia in isolated coronary artery ectasias and aneurysms ('dilated coronopathy'). J Am Coll Cardiol 1999; 34: 1461-70.
5. Swanton RH, Thomas ML, Coltart DJ, et al. Coronary artery ectasia - a variant of occlusive coronary arteriosclerosis. Br Heart J 1978; 40: 393-400.
6. Swaye PS, Fisher LD, Litwin P, et al. Aneurysmal coronary artery disease. Circulation 983; 67: 134-8.
7. Befeler B, Aranda J, Embi A, et al. Coronary artery aneurysms. Study of their etiology, clinical course and effect on left ventricular function and prognosis. Am J Med 1977; 62: 597-607.
8. Leiper JM, Vallance P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharmacol 2006; 62: 33-8.
9. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493.
10. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-9.
11. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-6.
12. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-88.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
14. Martens-Lobenhoffer J, Westphal S, Awiszus F, et al. Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA? Clin Chem 2005; 51: 2188-9.
15. Siroká R, Trefil L, Rajdl D, et al. Asymmetric dimethylarginine - comparison of HPLC and ELISA methods. J Chromatogr B 2007; 850: 586-7.
16. Valtonen P, Karppi J, Nyyssönen K, et al. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B 2005; 828: 97-102.
17. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
18. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
19. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990; 85: 587-90.
20. Takemoto M, Egashira K, Usui M, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997; 99: 278-87.
21. Lücke T, Kanzelmeyer N, Kemper MJ, et al. Developmental changes in the Larginine/ nitric oxide pathway from infancy to adulthood: plasma asymmetric dimethylarginine levels decrease with age. Clin Chem Lab Med 2007; 45: 1525-30.
22. Bełtowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006; 58: 159-78.
23. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
24. Engler MM, Engler MB, Malloy MJ, et al. Antioxidant vitamins C and E improve endothelial function in children and adolescents with hyperlipidemia: Endothelial Assessment of Risk From Lipids in Youth (EARLY) trial. Circulation 2003; 108: 1059-63.
25. Masuda H, Goto M, Tamaoki S, et al. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 1999; 126: 211-8.
26. Sen N, Tavil Y, Yazici HU, et al. Mean platelet volume in patients with coronary artery ectasia. Med Sci Monit 2007; 13: CR356-9.
27. Senen K, Yetkin E, Turhan H, et al. Increased thrombolysis in myocardial infarction frame counts in patients with isolated coronary artery ectasia. Heart Vessels 2004; 19: 23-6.
28. Papadakis MC, Manginas A, Cotileas P, et al. Documentation of slow coronary flow by the TIMI frame count in patients with coronary ectasia. Am J Cardiol 2001; 88: 1030-2.